Home > Search Clinical Trials > All > Trial Details

Clinical Trial Details
A randomized, double-blind placebo-controlled study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington disease.
Clinical Trial ( IRB ) #: 12-207-1
Title: A randomized, double-blind placebo-controlled study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington disease.
Principal Investigator: Dr. Carolyn Drazinic
Description: The purpose of this study is to develop a better understanding of side effects that can occur in people with early to mid-stage HD while taking the drug PBT2. The study will also assess how PBT2 affects the body and brain and whether PBT2 can slow down the worsening of HD symptoms that occur over time. Two different doses of the study medication will be compared with placebo.
Classification:
  Brain, Spinal Cord and Nervous System
  Huntington's Disease
  Inherited/Congenital/Genetic
Eligibility Criteria: Check with study contact
How to Contact: Bonnie Hennig, MSW, LCSW, QCSW, DCSW. Telephone: (860) 679-4063. Email: Hennig@uchc.edu
Enrollment Status/Comments: Enrolling/recruiting. For current recruitment status, please check with study contact.
Study Ad: Reach2HD